NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Forecast & News

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($2.17) by $0.25. The biopharmaceutical company had revenue of $70.06 million for the quarter, compared to analyst estimates of $57.14 million. Alnylam Pharmaceuticals had a negative net margin of 485.73% and a negative return on equity of 52.88%. The business's quarterly revenue was up 3284.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.56) EPS. View Alnylam Pharmaceuticals' Earnings History.

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Alnylam Pharmaceuticals.

17 analysts have issued 1-year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $62.00 to $190.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $121.59 in the next twelve months. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.

News coverage about ALNY stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 4,420,000 shares, a drop of 10.5% from the December 15th total of 4,940,000 shares. Based on an average daily trading volume, of 694,700 shares, the days-to-cover ratio is currently 6.4 days. Approximately 4.0% of the company's stock are short sold. View Alnylam Pharmaceuticals' Current Options Chain.

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), NXP Semiconductors (NXPI), Gilead Sciences (GILD), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU).

Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.14%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Polianta Ltd (0.01%), Zeke Capital Advisors LLC (0.00%) and Gateway Investment Advisers LLC (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Paul Schimmel, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

ALNY stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Zeke Capital Advisors LLC, IFM Investors Pty Ltd and Gateway Investment Advisers LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Barry E Greene, John Maraganore, Marsha Fanucci, Philip A Sharp, Phillip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Polianta Ltd, Tocqueville Asset Management L.P., IBM Retirement Fund and DNB Asset Management AS. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALNY stock can currently be purchased for approximately $117.93.

Alnylam Pharmaceuticals has a market capitalization of $13.15 billion and generates $74.91 million in revenue each year. The biopharmaceutical company earns $-761,490,000.00 in net income (profit) each year or ($7.57) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,065 workers across the globe.View Additional Information About Alnylam Pharmaceuticals.

The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]